Literature DB >> 2255586

Comparative bioavailability study of two brands of prazosin-containing tablets in healthy volunteers.

P J Guelen1, T J Janssen, M H Lam, T B Vree, P S Exler.   

Abstract

The bioavailability of two prazosin formulations was studied in 12 healthy volunteers. 1 Subject left the study. Based on the statistical tests of the pharmacokinetic parameters of prazosin in 11 volunteers, such as t 1/2, Cmax, tmax and AUC, it could be concluded that both preparations had comparable bioavailabilities.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2255586     DOI: 10.1007/bf01980043

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  14 in total

1.  Symmetrical confidence intervals for bioequivalence trials.

Authors:  W J Westlake
Journal:  Biometrics       Date:  1976-12       Impact factor: 2.571

2.  A new statistical procedure for testing equivalence in two-group comparative bioavailability trials.

Authors:  W W Hauck; S Anderson
Journal:  J Pharmacokinet Biopharm       Date:  1984-02

3.  Naproxen-metabolism, excretion and comparative pharmacokinetics.

Authors:  R Runkel; E Forchielli; G Boost; M Chaplin; R Hill; H Sevelius; G Thompson; E Segre
Journal:  Scand J Rheumatol Suppl       Date:  1973

4.  Pharmacokinetics of naproxen in subjects with normal and impaired renal function.

Authors:  M Anttila; M Haataja; A Kasanen
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

5.  High-performance liquid chromatographic determination of prazosin in human plasma, whole blood and urine.

Authors:  E T Lin; R A Baughman; L Z Benet
Journal:  J Chromatogr       Date:  1980-09-12

6.  Synthesis and identification of the major metabolites of prazosin formed in dog and rat.

Authors:  T H Althuis; H J Hess
Journal:  J Med Chem       Date:  1977-01       Impact factor: 7.446

7.  Prazosin disposition in young and elderly subjects.

Authors:  P C Rubin; P J Scott; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

8.  Altered prazosin pharmacokinetics in congestive heart failure.

Authors:  R A Baughman; S Arnold; L Z Benet; E T Lin; K Chatterjee; R L Williams
Journal:  Eur J Clin Pharmacol       Date:  1980-06       Impact factor: 2.953

9.  The metabolic fate of prazosin.

Authors:  J A Taylor; T M Twomey; M S von Wittenau
Journal:  Xenobiotica       Date:  1977-06       Impact factor: 1.908

Review 10.  Clinical pharmacokinetics of prazosin.

Authors:  P Jaillon
Journal:  Clin Pharmacokinet       Date:  1980 Jul-Aug       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.